BioNTech is acquiring CureVac in an all-stock deal valued at $1.25 billion, effectively ending prolonged patent litigation over mRNA vaccine technology. The transaction strengthens BioNTech's manufacturing capacity and oncology pipeline, facilitating future development of transformative cancer immunotherapies.